Ticker: NBIX

Neurocrine Biosciences

Biotech Healthcare Drug Manufacturers - Specialty & Generic

Price 145.35

Reco Sell Potential 52 Risk 75 Updated 2026-10-25

Official website

Forecast impact

negative

Target +50.0% target fill 66.7%

Reaction D5 -1.24% · D10 +0.46% market trust

Impact Potential -4 · Risk +3 valid until 2026-10-29

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological and endocrine diseases. Its core products include therapies for conditions such as tardive dyskinesia and endometriosis. The company operates primarily in the healthcare sector, with major revenue sources stemming from product sales and collaborations with other pharmaceutical firms. Neurocrine's commitment to innovation is reflected in its robust pipeline of drug candidates aimed at addressing unmet medical needs.

Investment Profile

The investment profile of Neurocrine Biosciences is more aligned with growth investors, given its focus on innovative therapies and potential for revenue expansion. The absence of dividends suggests a reinvestment strategy aimed at long-term value creation. Investors may find the stock suitable for a medium to long-term horizon, with moderate liquidity reflecting its market position.

Category: Biotech Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Investment style: Growth Horizon: Medium-term Company type: Niche Player

Fundamental metrics (experimental) Updated: 2026-10-24

EPS (TTM) — earnings per share for the last 12 months, $: 7.05
Revenue QoQ — quarter-over-quarter revenue growth: 17.7%
EPS surprise: -15.8%
20d volatility: 1.6%

AI recommendation changes

Date	Before	After	Reason
2026-09-28	Hold	Sell	Weak momentum and high risk; uncertain outlook ahead.
2026-09-21	Buy	Hold	Weak momentum and high risk limit upside potential.
2026-09-13	Hold	Buy	Mixed performance; analyst signals lack strong confirmation.
2026-09-06	Sell	Hold	Mixed performance; high risk with uncertain momentum.
2026-08-29	Hold	Sell	Weak momentum and EPS surprise raise concerns.
2026-08-27	Sell	Hold	Strong revenue growth, but EPS surprise raises concerns.
2026-08-14	Buy	Sell	Weak momentum and high risk overshadow potential upside.
2026-08-08	Hold	Buy	Strong fundamentals but mixed momentum signals.
2026-08-01	Buy	Hold	Weak momentum and high risk; cautious approach advised.
2026-05-16	Hold	Buy	Strong momentum and positive earnings surprise support growth outlook.
2026-05-08	—	Hold	Strong recent performance and positive momentum indicators.
2026-05-07	Hold	Buy	Компания демонстрирует положительную динамику цен на акции в краткосрочной перспективе, а также стабильный рост выручки. Умеренный риск обусловлен волатильностью на рынке и отсутствием дивидендов.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-09-29	UBS	Target Lowered	231 → 214	140.44
2026-09-11	Morgan Stanley	Target Raised	182 → 183	156.57
2026-09-08	RBC Capital	Update	— → 198	155.655
2026-08-13	Bernstein	Target Lowered	221 → 218	156.49
2026-08-13	Morgan Stanley	Target Lowered	196 → 182	156.49
2026-08-13	Deutsche Bank	Target Lowered	190 → 165	156.49
2026-08-03	Wedbush	Target Raised	185 → 194	170.0618
2026-08-03	H.C. Wainwright	Update	— → 215	166.8
2026-08-03	Canaccord Genuity	Target Raised	— → 210	166.8
2026-07-31	Morgan Stanley	Target Raised	193 → 196	167.38
2026-07-31	Deutsche Bank	Target Raised	170 → 190	165.9319
2026-07-31	Needham	Target Raised	200 → 204	185.5
2026-07-31	Piper Sandler	Target Raised	207 → 210	185.5
2026-07-31	Robert W. Baird	Target Raised	186 → 225	185.5
2026-07-31	Guggenheim	Target Raised	200 → 222	185.5
2026-07-21	Guggenheim	Target Raised	175 → 200	178.1
2026-07-17	Wells Fargo	Target Raised	175 → 200	171.55
2026-07-13	Truist Financial	Target Raised	155 → 200	175.155
2026-07-13	BMO Capital	Target Raised	144 → 170	173.88989
2026-07-13	Wedbush	Target Raised	176 → 185	173.73
2026-07-07	RBC Capital	Target Raised	183 → 195	174.1
2026-06-30	UBS	Target Raised	182 → 208	170
2026-06-02	Goldman Sachs	Update	— → 213	161
2026-05-21	Bernstein	Update	— → 221	155.5
2026-05-06	Oppenheimer	Target Raised	220 → 230	135.06
2026-05-06	Piper Sandler	Target Raised	190 → 207	135.06
2026-04-06	Oppenheimer	Target Raised	— → 220	132.48
2026-03-10	Cantor Fitzgerald	Target Raised	— → 195	130.39
2026-02-23	Wolfe Research	Update	— → 160	128.38
2026-02-17	Truist Financial	Target Lowered	169 → 140	128.98
2026-02-12	Needham	Target Lowered	187 → 185	125.38
2026-02-12	RBC Capital	Target Lowered	180 → 177	124.155
2026-02-12	Wedbush	Target Raised	149 → 151	125.09

News Page 1 of 1

Nothing yet